Bryan Johnson took a high dose of 5-MeO-DMT, describing it as the most powerful psychedelic and a more profound "reset" than any other longevity intervention (diet, exercise, sleep, hyperbaric oxygen, metformin).
His thesis is that psychedelics (psilocybin and 5-MeO-DMT) are powerful longevity therapies, not just for mental health, acting by "dissolving" the brain's default mode network to increase neuroplasticity, reduce inflammatory patterns, and restore a more youthful, childlike state.
Johnson's quantified experiments with Kernel's brain interface show psychedelics dramatically alter brain connectivity patterns, with 5-MeO-DMT "annihilating" the default mode network far more than psilocybin.
He acknowledges significant risks: potential for permanent psychosis, "bad trips," and life-altering decisions (e.g., CEOs abandoning companies) which have led some investors to prohibit founder psychedelic use in deal documents.
Next-generation longevity modalities in his pipeline include mitochondrial rejuvenation therapy (using donor mitochondria), gene therapy (e.g., FoxO3 plasmid delivery for tissue regeneration), and testing interventions on his own induced pluripotent stem cell (iPSC)-derived organoids (heart, liver, lungs).
He is an investor in New Limit (cellular reprogramming) and believes Yamanaka factor-based rejuvenation, combined with AI for discovery and precise cellular control mechanisms, represents a profound future technology alongside AI.
Johnson positions GLP-1 drugs as the "first big drop" in societal health transformation, with future cellular/gene therapies potentially shifting longevity from a sci-fi pursuit to a widespread reality, improving societal abundance and happiness.
A key philosophical tension is explored: if a drug can rewire your personality, values, and perspective in hours, are you still the same person? This underpins both the risk and potential utility of "psychoflexibility" in a fast-changing world.